Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18186410 | 0.92 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL16824953 | 0.89 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL16824841 | 0.89 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL16824900 | 0.87 | SMN1; SMN2 (0.51) | ALDH1A1SMN1; SMN2CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL18186205 | 0.86 | LMNA (0.54) | ALDH1A1SMN1; SMN2CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL18186200 | 0.85 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL8168514 | 0.83 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL18186403 | 0.83 | NR1H2 (0.37) | ALDH1A1SMN1; SMN2MAPTGAAHTT | |
| SCHEMBL8164427 | 0.82 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL18186395 | 0.82 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2CYP1A2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9850247-B2 | Pyrimidopyrimidinones useful as Wee-1 kinase inhibitors | ALMAC HOUSE (GB) | 2017-12-26 | — | — | US | disclosed |
| EP-3083625-B1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | ALMAC DISCOVERY LTD (GB) | 2017-11-01 | — | — | EP | disclosed |
| US-20160318936-A1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2016-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318936-A1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | WEE1, WEE2, NME1 | ALDH1A1 1940/4885SMN1; SMN2 4422/4885CYP1A2 4469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.